MarginsXMarginsX
Home › Markets › Health Care › RMTI

Rockwell Medical Inc. (RMTI)

RMTI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.76
-4.38% on the day
Market cap
$26.9M
Nano cap
Revenue · 2025
$69.3M
-31.8% on 2024
Net income · 2025
-$5.3M
-7.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1041024/000162828026021186/0001628280-26-021186-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRMTI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year1998
SEC CIK0001041024
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$69.3M
Net income-$5.3M
Operating income-$4.7M
Net margin-7.7%
Operating margin-6.8%
Revenue growth-31.8%
Cash$10.7M
Total assets$57.1M
P/E (computed)Net income was not positive
P/S (computed)0.4×

Warning signs

Cash runway
Cash-flow positive
$10.6M cash at September 30, 2026
Share count, 1 year
+17.1%
2025-08-06 to 2026-08-10 · +41.5% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$20K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$10.6M cash; operating cash flow $670K a quarter.Report 2026-09-30
Shares outstanding4,030,465 (2026-08-10); 34,430,352 a year earlier; 28,489,663 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-10 overall).Cover page 2026-08-10
Reverse splits, 3 years1; latest 1-for-10 on 2026-07-01Source 2026-07-01
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-05-08
AuditorEisnerAmper LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $20K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$19.1M-$2.3M-$1.5M$10.6M$9.1M$72.6M10-Q 2026-11-12
Q2 2026
2026-06-30
$17.8M-$1.2M$2.1M$10.5M$9.0M$69.4M10-Q 2026-08-13
Q1 2026
2026-03-31
$17.3M-$1.6M-$167K$9.6M$8.9M$67.7M10-Q 2026-05-07
Q4 2025
2025-12-31
$18.3M-$554K$2.3M$10.7M$8.8M$69.3M10-K 2026-03-26
Q3 2025
2025-09-30
$15.9M-$1.8M-$1.3M$13.6M$8.7M$75.6M10-Q 2026-11-12
Q2 2025
2025-06-30
$16.1M-$1.5M$1.8M$12.5M$8.6M$88.0M10-Q 2026-08-13
Q1 2025
2025-03-31
$18.9M-$1.5M-$3.5M$11.4M$8.6M$97.7M10-Q 2026-05-07
Q4 2024
2024-12-31
$24.7M-$756K$865K$15.7M$8.5M$101.5M10-K 2026-03-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-11-13
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-05-11

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.1%
1 month-10.4%
3 months-10.2%
Year to date-15.3%
1 year-22.7%
From 52-week high-44.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MIRAMIRA Pharmaceuticals Inc.$0.6310-4.38%$26.5M
AARDAardvark Therapeutics Inc.$1.26-5.26%$27.6M
ACETAdicet Bio Inc.$2.75-1.08%$25.7M
LITSLite Strategy Inc.$0.8565+1.16%$25.6M
EDSAEdesa Biotech Inc. Common Shares$1.89-2.58%$25.5M
ABVCABVC BioPharma Inc.$0.9400+3.30%$25.4M
CRVOCervoMed Inc.$1.67-1.18%$25.3M
IMMPImmutep Limited$3.40-2.30%$25.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier